MA38797A1 - Protéine de fusion thérapeutique - Google Patents
Protéine de fusion thérapeutiqueInfo
- Publication number
- MA38797A1 MA38797A1 MA38797A MA38797A MA38797A1 MA 38797 A1 MA38797 A1 MA 38797A1 MA 38797 A MA38797 A MA 38797A MA 38797 A MA38797 A MA 38797A MA 38797 A1 MA38797 A1 MA 38797A1
- Authority
- MA
- Morocco
- Prior art keywords
- fusion protein
- therapeutic fusion
- therapeutic
- neprilysin
- binds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6494—Neprilysin (3.4.24.11), i.e. enkephalinase or neutral-endopeptidase 24.11
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24011—Neprilysin (3.4.24.11), i.e. enkephalinase or neutral endopeptidase 24.11
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne une protéine de fusion comprenant un anticorps dirigé contre aß, une entité de liaison monovalente qui se lie à un récepteur de la barrière hémato-encéphalique et une néprilysine.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13179056 | 2013-08-02 | ||
PCT/EP2014/066355 WO2015014884A1 (fr) | 2013-08-02 | 2014-07-30 | Protéine de fusion thérapeutique |
Publications (1)
Publication Number | Publication Date |
---|---|
MA38797A1 true MA38797A1 (fr) | 2018-06-29 |
Family
ID=48900891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA38797A MA38797A1 (fr) | 2013-08-02 | 2014-07-30 | Protéine de fusion thérapeutique |
Country Status (20)
Country | Link |
---|---|
US (1) | US20160168253A1 (fr) |
EP (1) | EP3027280A1 (fr) |
JP (1) | JP2016527260A (fr) |
KR (1) | KR20160037173A (fr) |
CN (1) | CN105431203A (fr) |
AU (1) | AU2014298519A1 (fr) |
BR (1) | BR112016001782A2 (fr) |
CA (1) | CA2919325A1 (fr) |
CL (1) | CL2016000219A1 (fr) |
CR (1) | CR20160041A (fr) |
EA (1) | EA201600141A1 (fr) |
HK (1) | HK1216159A1 (fr) |
IL (1) | IL243353A0 (fr) |
MA (1) | MA38797A1 (fr) |
MX (1) | MX2016001145A (fr) |
PE (1) | PE20160720A1 (fr) |
PH (1) | PH12016500123A1 (fr) |
SG (1) | SG11201600807YA (fr) |
WO (1) | WO2015014884A1 (fr) |
ZA (1) | ZA201600086B (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY160445A (en) | 2010-08-03 | 2017-03-15 | Abbvie Inc | Dual Variable Domain Immunoglobulins And Uses Thereof |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
CA2990565A1 (fr) | 2015-06-24 | 2016-12-29 | Jcr Pharmaceuticals Co., Ltd. | Proteine de fusion contenant un bdnf et un anticorps du recepteur de la transferrine anti-humain |
MY187033A (en) | 2015-06-24 | 2021-08-27 | Japan Chem Res | Anti-human transferrin receptor antibody permeating blood-brain barrier |
CR20170562A (es) | 2015-06-24 | 2018-02-01 | Hoffmann La Roche | Anticuerpos anti-receptor de transferrina con afinidad diseñada. |
PL3313877T3 (pl) * | 2015-06-24 | 2020-11-02 | F. Hoffmann-La Roche Ag | Humanizowane przeciwciała przeciwko białku tau(pS422) i sposoby stosowania |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
EP3356406A1 (fr) | 2015-10-02 | 2018-08-08 | H. Hoffnabb-La Roche Ag | Anticorps de récepteur de la transferrine humaine/anti-humaine cd20 bispécifique et leurs procédés d'utilisation |
BR112019009316A2 (pt) | 2016-12-26 | 2019-08-06 | Japan Chem Res | anticorpo antirreceptor de transferrina humana, proteína de fusão, fragmento de dna, vetor de expressão, célula de mamífero, complexo de composto farmacologicamente ativo e de anticorpo antirreceptor de transferrina humana, usos do anticorpo antirreceptor de transferrina humana e da proteína de fusão, e, métodos para tratamento de um distúrbio do sistema nervoso central e de uma doença do sistema nervoso central que acompanha a doença de pompe, a síndrome de hurler ou a síndrome de hurler-scheie. |
US10457717B2 (en) | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
US10143187B2 (en) | 2017-02-17 | 2018-12-04 | Denali Therapeutics Inc. | Transferrin receptor transgenic models |
PT3583120T (pt) | 2017-02-17 | 2022-12-15 | Denali Therapeutics Inc | Polipeptídeos de ligação ao recetor de transferrina manipulados |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101321863A (zh) * | 2005-10-03 | 2008-12-10 | 阿斯利康(瑞典)有限公司 | 具有受调控的血浆半衰期的融合蛋白 |
JP5959795B2 (ja) * | 2006-08-18 | 2016-08-02 | アーメイゲン・テクノロジーズ・インコーポレイテッドArmagen Technologies, Inc. | 血液脳関門送達のための物質 |
TW200907056A (en) * | 2007-03-28 | 2009-02-16 | Astrazeneca Ab | New method |
JP2010524479A (ja) * | 2007-05-02 | 2010-07-22 | エフ.ホフマン−ラ ロシュ アーゲー | タンパク質を安定化する方法 |
US8946165B2 (en) * | 2008-09-29 | 2015-02-03 | The Regents Of The University Of California | Compounds for reversing and inhibiting protein aggregation, and methods for making and using them |
WO2011160732A1 (fr) * | 2010-06-21 | 2011-12-29 | Medimmune, Llc. | Variantes de la néprilysine humaine de type protéase |
US20120171120A1 (en) * | 2010-11-30 | 2012-07-05 | Genentech, Inc. | Low affinity blood brain barrier receptor antibodies and uses therefor |
-
2014
- 2014-07-30 MA MA38797A patent/MA38797A1/fr unknown
- 2014-07-30 CA CA2919325A patent/CA2919325A1/fr not_active Abandoned
- 2014-07-30 WO PCT/EP2014/066355 patent/WO2015014884A1/fr active Application Filing
- 2014-07-30 EP EP14747595.8A patent/EP3027280A1/fr not_active Withdrawn
- 2014-07-30 EA EA201600141A patent/EA201600141A1/ru unknown
- 2014-07-30 BR BR112016001782A patent/BR112016001782A2/pt not_active Application Discontinuation
- 2014-07-30 AU AU2014298519A patent/AU2014298519A1/en not_active Abandoned
- 2014-07-30 KR KR1020167002488A patent/KR20160037173A/ko not_active Application Discontinuation
- 2014-07-30 US US14/907,173 patent/US20160168253A1/en not_active Abandoned
- 2014-07-30 SG SG11201600807YA patent/SG11201600807YA/en unknown
- 2014-07-30 CN CN201480043474.2A patent/CN105431203A/zh active Pending
- 2014-07-30 JP JP2016530511A patent/JP2016527260A/ja active Pending
- 2014-07-30 MX MX2016001145A patent/MX2016001145A/es unknown
- 2014-07-30 PE PE2016000199A patent/PE20160720A1/es unknown
-
2015
- 2015-12-24 IL IL243353A patent/IL243353A0/en unknown
-
2016
- 2016-01-06 ZA ZA2016/00086A patent/ZA201600086B/en unknown
- 2016-01-19 PH PH12016500123A patent/PH12016500123A1/en unknown
- 2016-01-20 CR CR20160041A patent/CR20160041A/es unknown
- 2016-01-28 CL CL2016000219A patent/CL2016000219A1/es unknown
- 2016-04-08 HK HK16104037.9A patent/HK1216159A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
HK1216159A1 (zh) | 2016-10-21 |
SG11201600807YA (en) | 2016-03-30 |
MX2016001145A (es) | 2016-04-29 |
AU2014298519A1 (en) | 2016-02-04 |
CA2919325A1 (fr) | 2015-02-05 |
US20160168253A1 (en) | 2016-06-16 |
JP2016527260A (ja) | 2016-09-08 |
CL2016000219A1 (es) | 2016-09-16 |
EA201600141A1 (ru) | 2016-09-30 |
ZA201600086B (en) | 2017-04-26 |
PH12016500123A1 (en) | 2016-04-25 |
PE20160720A1 (es) | 2016-07-28 |
CR20160041A (es) | 2016-02-08 |
BR112016001782A2 (pt) | 2017-08-29 |
EP3027280A1 (fr) | 2016-06-08 |
WO2015014884A1 (fr) | 2015-02-05 |
IL243353A0 (en) | 2016-02-29 |
CN105431203A (zh) | 2016-03-23 |
KR20160037173A (ko) | 2016-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA38797A1 (fr) | Protéine de fusion thérapeutique | |
MA43576A (fr) | Anticorps anti-lag3 et fragments de fixation à l'antigène | |
MA53434A (fr) | Anticorps anti-tigit | |
EP3630189A4 (fr) | Lieurs pour conjugués anticorps-médicament | |
MA52884A (fr) | Anticorps anti-il-11 | |
MA55347A (fr) | Anticorps anti-lag3 et fragments de fixation à l'antigène | |
MX2017016838A (es) | Construcciones dirigidas a complejos de peptido de ny-eso-1/complejo principal de histocompatibilidad (mhc) y usos de los mismos. | |
CR20170383A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
BR112016007112A2 (pt) | Anticorpos que se ligam a angiopoietina 2 (ang-2) humana, usos de um anticorpo que se liga a angiopoietina 2 (ang-2) humana e combinação | |
DK3544636T3 (da) | Pyrrolobenzodiazepin-antistof-konjugater | |
MA41313A (fr) | Anticorps de liaison de la protéine april modifiés | |
PH12018501043A1 (en) | Site specific her2 antibody drug conjugates | |
CL2012001853A1 (es) | Formulación farmacéutica que comprende un anticuerpo humano que se une de modo especifico al receptor de interleuquina 6 humana (hil-6r), histidina y un carbohidrato. | |
BR112016003665A2 (pt) | anticorpos e ensaios para detecção do receptor 1 de folato | |
BR112018075651A2 (pt) | anticorpos anti-cd98 e conjugados anticorpo fármaco | |
MA52366A (fr) | Anticorps anti-tl1a optimisés | |
MA43151A (fr) | Anticorps monoclonaux spécifiques pour le sérogroupe x de n. meningitidis et leurs utilisations dans le diagnostic | |
EP3661961A4 (fr) | Anticorps se liant à l'alpha-synucléine active | |
IL282641A (en) | Single-region antibodies that bind human serum albumin | |
IL287938A (en) | Drug antibody conjugates | |
MA43345A (fr) | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation | |
EP3608339A4 (fr) | Variants d'anticorps fc pour améliorer la demi-vie dans le sang | |
TR201819828T4 (tr) | Anti-fosfolipaz d4 antikoru. | |
MA43049A (fr) | Anticorps de liaison à un récepteur cannabinoïde 1 humain (cb1) | |
MA49977A (fr) | Combinaisons pharmaceutiques comprenant un anticorps anti-ly75 |